Evidence map›Paper›PMID 35985981›Full record

ArticleEuropean urology oncology2022

Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52].

Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, Patrick Hilden, Martin Gleave, Michael A Carducci, Fred Saad, Erica D Cohn, Julie Filipenko, Glenn Heller and 3 more

Open access · greenAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 2 countries.

Michael J MorrisGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address: morrism@mskcc.org.
Jose Mauricio MotaGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kristine LacunaDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.
Patrick HildenEpidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Martin GleaveDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Michael A CarducciSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Fred SaadDivision of Urology, University of Montreal Hospital Center (CHUM), Montreal, QC, Canada.
Erica D CohnGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Julie FilipenkoProstate Cancer Clinical Trials Consortium, New York, NY, USA.
Glenn HellerEpidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Neal ShoreDepartment of Urology, Carolina Urologic Research Center, Myrtle Beach, SC, USA.
Andrew J ArmstrongDivisions of Medical Oncology and Urology, Departments of Medicine and Surgery at the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, NC, USA.
Howard I ScherGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Memorial Sloan Kettering Cancer Center · USCornell University · USCancer Clinic · USCarolina Urologic Research Center · USDuke University · USSidney Kimmel Comprehensive Cancer Center · USUniversité de Montréal · CAUniversity of British Columbia · CA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Yu Chen, MICHAEL J MORRIS · 2001 to 2026
$63.0M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35985981
PMCPMC10545163
OpenAlexW4292178027

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.